Roger D. Dansey, M.D.

Dr. Roger Dansey brings extensive experience in cancer drug development, having served as the Chief Development Officer and Chief Oncology Officer of Pfizer Oncology from January 2024 until his retirement in March 2025 and as President, Research and Development of Seagen from November 2022 until Pfizer’s acquisition of Seagen in December 2023. He was previously the Chief Medical Officer at Seagen, starting in 2018.

Previously, Dr. Dansey was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for global registration efforts for Keytruda^® (pembrolizumab) across multiple tumor types. Earlier in his career, he was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva^® (denosumab) at Amgen, where he held multiple roles in oncology and hematology. Before joining industry, Dr. Dansey was an associate professor of hematology and oncology at the Karmanos Cancer Institute in Detroit.

Dr. Dansey holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa.